CA2349427A1 - Method for preventing increased iridial pigmentation during prostaglandin treatment - Google Patents

Method for preventing increased iridial pigmentation during prostaglandin treatment Download PDF

Info

Publication number
CA2349427A1
CA2349427A1 CA002349427A CA2349427A CA2349427A1 CA 2349427 A1 CA2349427 A1 CA 2349427A1 CA 002349427 A CA002349427 A CA 002349427A CA 2349427 A CA2349427 A CA 2349427A CA 2349427 A1 CA2349427 A1 CA 2349427A1
Authority
CA
Canada
Prior art keywords
inflammatory agent
prostaglandin
steroid type
cyclo
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002349427A
Other languages
English (en)
French (fr)
Inventor
Johan Stjernschantz
Bahram Resul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synphora AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2349427A1 publication Critical patent/CA2349427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002349427A 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment Abandoned CA2349427A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803761-7 1998-11-04
SE9803761A SE9803761D0 (sv) 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment
PCT/SE1999/001993 WO2000025771A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment

Publications (1)

Publication Number Publication Date
CA2349427A1 true CA2349427A1 (en) 2000-05-11

Family

ID=20413170

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002349427A Abandoned CA2349427A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment

Country Status (6)

Country Link
EP (1) EP1126835A1 (sv)
JP (1) JP2002528491A (sv)
AU (1) AU758973B2 (sv)
CA (1) CA2349427A1 (sv)
SE (1) SE9803761D0 (sv)
WO (1) WO2000025771A1 (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
JP4234907B2 (ja) * 1998-05-15 2009-03-04 わかもと製薬株式会社 抗炎症点眼剤
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
EP1418903A2 (en) * 2001-04-23 2004-05-19 The Board of Regents of the University of Texas System Prostanoids augment ocular drug penetration
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
MXPA01013257A (es) * 2001-12-18 2003-06-25 Arturo Jimenez Bayardo Suspension oftalmica de rofecoxib para el tratamiento de la inflamacion y el dolor ocular.
CN100425241C (zh) * 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
CA2506464C (en) 2002-11-18 2012-07-31 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
EP1755616B1 (en) * 2004-04-08 2013-08-14 Advanced Ocular Systems Limited Treatment of exudative retinopathy with mineralcorticoids
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
CA2823647C (en) * 2011-01-07 2016-07-19 Allergan, Inc. Compositions comprising substituted benzaldehydes and use thereof for lightening skin or treating hyperpigmenation and hypermelanosis disorders
EP2667875A4 (en) * 2011-01-24 2014-07-30 Inceptum Res & Therapeutics Inc COMPOSITIONS COMPRISING PROSTAGLANDIN FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53127832A (en) * 1977-04-11 1978-11-08 Teijin Ltd Antiphkogistics for oral administration containing thiaprostaglandins
GB2135881A (en) * 1983-03-02 1984-09-12 Erba Farmitalia Method and pharmaceutical compositions for inhibiting or reducing gastrointestinal side effects of non-steroidal anti-inflammatory drugs
GB8625325D0 (en) * 1986-10-22 1986-11-26 Glaxo Group Ltd Chemical compounds
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
ES2071312T3 (es) * 1990-05-03 1995-06-16 Searle & Co Composicion farmaceutica.
AU8089091A (en) * 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition containing ibuprofen and a prostaglandin
DE69433818T2 (de) * 1994-01-28 2005-06-16 The University Of Kentucky Research Foundation Co-pharmaka als ein verfahren des kontrollierten arzneimitteltransportes
SE9702706D0 (sv) * 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Also Published As

Publication number Publication date
JP2002528491A (ja) 2002-09-03
AU758973B2 (en) 2003-04-03
EP1126835A1 (en) 2001-08-29
SE9803761D0 (sv) 1998-11-04
WO2000025771A1 (en) 2000-05-11
AU1435000A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
AU758973B2 (en) Method for preventing increased iridial pigmentation during prostaglandin treatment
Alm Prostaglandin derivates as ocular hypotensive agents
EP0777483B1 (en) Methods and means for drug administration
Patel et al. Latanoprost: a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension
KR20100080798A (ko) 안과 질환의 치료를 위한 옥실리핀 화합물
RU2352337C2 (ru) Ингибиторы гистондеацетилазы для лечения офтальмологических неоваскулярных нарушений и заболеваний
JPH09504543A (ja) 白内障の予防法及び予防手段
Ishida et al. Prostanoids in the therapy of glaucoma
AU732046B2 (en) The use of alpha-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
JP2004520361A (ja) メニエール病、耳鳴および／または聴覚損失の局所処置のための新規な方法および組成物
Camras et al. Initial clinical studies with prostaglandins and their analogues
US20110082200A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
US6255353B1 (en) Inhibition of angiogenesis
JPWO2002085372A1 (ja) 薬剤および薬剤キット
WO2001095913A1 (en) Methods and compositions for the prevention of myopia
AU2007234903B2 (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
JPH10505860A (ja) 続発性白内障の予防と治療のための方法と手段
WO2009148163A1 (ja) 膀胱排尿筋収縮および尿道括約筋弛緩剤
AU767411B2 (en) Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
Wyse et al. Topical Prostaglandins for Galucoma Therapy
Zhai et al. Latanoprost-induced side effects and potential mechanisms
Sarkisian et al. Update on Prostaglandin-Related Drugs in Glaucoma Management
BE1028115A1 (fr) Composition pour le traitement des cancers

Legal Events

Date Code Title Description
FZDE Dead